• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Opioid use disorder: current trends and potential treatments.阿片类药物使用障碍:当前趋势和潜在治疗方法。
Front Public Health. 2024 Jan 25;11:1274719. doi: 10.3389/fpubh.2023.1274719. eCollection 2023.
2
Examining buprenorphine diversion through a harm reduction lens: an agent-based modeling study.从减少伤害的角度审视丁丙诺啡的滥用:基于代理的建模研究。
Harm Reduct J. 2023 Oct 17;20(1):150. doi: 10.1186/s12954-023-00888-6.
3
Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic.在 COVID-19 大流行期间,洛杉矶高过量地区的药店中丁丙诺啡和纳洛酮的获取情况。
Harm Reduct J. 2022 Jun 29;19(1):69. doi: 10.1186/s12954-022-00651-3.
4
Cost-effectiveness of Treatments for Opioid Use Disorder.阿片类药物使用障碍治疗的成本效益。
JAMA Psychiatry. 2021 Jul 1;78(7):767-777. doi: 10.1001/jamapsychiatry.2021.0247.
5
Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review.监禁人员中与阿片类药物相关的治疗、干预措施和结果:系统评价。
PLoS Med. 2019 Dec 31;16(12):e1003002. doi: 10.1371/journal.pmed.1003002. eCollection 2019 Dec.
6
Stigma by Association: To what Extent is the Attitude Toward Naloxone Affected by the Stigma of Opioid Use Disorder?关联污名:阿片类药物使用障碍的污名对纳洛酮态度的影响有多大?
J Pharm Pract. 2023 Aug;36(4):941-952. doi: 10.1177/08971900221097173. Epub 2022 May 3.
7
Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial.一项扩大阿片类药物使用障碍治疗药物治疗处方者的劳动力发展干预措施的测试:一项群组随机试验的方案。
Implement Sci. 2017 Nov 15;12(1):135. doi: 10.1186/s13012-017-0665-x.
8
Medication Treatment of Opioid Use Disorder.阿片类药物使用障碍的药物治疗。
Biol Psychiatry. 2020 Jan 1;87(1):82-88. doi: 10.1016/j.biopsych.2019.06.020. Epub 2019 Jul 2.
9
Impacts of the COVID-19 pandemic on enrollment in medications for opioid use disorder (MOUD) in Vancouver, Canada: An interrupted time series analysis.加拿大温哥华 COVID-19 大流行对阿片类药物使用障碍(MOUD)药物治疗入组的影响:一项中断时间序列分析。
Int J Drug Policy. 2023 Aug;118:104075. doi: 10.1016/j.drugpo.2023.104075. Epub 2023 May 22.
10
Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter.评估关于阿片类药物使用障碍和纳洛酮药物在 Twitter 上的认知。
J Addict Dis. 2021 Jan-Mar;39(1):37-45. doi: 10.1080/10550887.2020.1811456. Epub 2020 Aug 24.

引用本文的文献

1
Evaluating Treatment Options for Opiate Use Disorder: A Meta-Analysis of Buprenorphine-Naloxone and Extended-Release Naltrexone.评估阿片类药物使用障碍的治疗方案:丁丙诺啡-纳洛酮和长效纳曲酮的荟萃分析。
Cureus. 2025 Aug 11;17(8):e89769. doi: 10.7759/cureus.89769. eCollection 2025 Aug.
2
Soyasaponin Bb Attenuates Morphine Withdrawal-Induced Anxiety-Like Behaviors in Male Mice by Rescuing GSK-3β/Nrf2 Signaling.大豆皂苷Bb通过挽救GSK-3β/Nrf2信号通路减轻雄性小鼠吗啡戒断诱导的焦虑样行为。
Psychiatry Investig. 2025 Jul;22(7):821-831. doi: 10.30773/pi.2025.0091. Epub 2025 Jul 16.
3
Safety and Toxicological Evaluation of Subunit Keyhole Limpet Hemocyanin-Loaded Lipid-PLGA Hybrid Nanoparticles (sKLH-hNPs) as a Nanocarrier for an Opioid Use Disorder Vaccine.作为阿片类物质使用障碍疫苗纳米载体的亚基钥孔血蓝蛋白负载脂质 - PLGA 杂化纳米颗粒(sKLH - hNPs)的安全性和毒理学评价
Int J Toxicol. 2025 Jul 5:10915818251355948. doi: 10.1177/10915818251355948.
4
Opioid Withdrawal Misdiagnosed as a Crohn's Flare.阿片类药物戒断被误诊为克罗恩病发作。
Case Rep Gastroenterol. 2025 Jun 13;19(1):434-438. doi: 10.1159/000546335. eCollection 2025 Jan-Dec.
5
Cerebrospinal Fluid Biomarkers in Opioid Dependence: Evidence of Neuroimmune Activation and Ion Composition Changes, Without Alteration in Orexin-A.阿片类药物依赖中的脑脊液生物标志物:神经免疫激活和离子组成变化的证据,而食欲素-A无改变。
Addict Biol. 2025 Jun;30(6):e70053. doi: 10.1111/adb.70053.
6
Adjunctive ketamine vs. buprenorphine in co-occurring major depressive disorder and opioid use disorder: a randomized, double-blind clinical trial assessing anxiety symptom severity and craving intensity.辅助性氯胺酮与丁丙诺啡治疗共病的重度抑郁症和阿片类物质使用障碍:一项评估焦虑症状严重程度和渴望强度的随机双盲临床试验
Trials. 2025 Apr 17;26(1):133. doi: 10.1186/s13063-025-08836-4.
7
Fungal Infections in People Who Use Drugs.吸毒者中的真菌感染
Open Forum Infect Dis. 2025 Feb 24;12(4):ofaf107. doi: 10.1093/ofid/ofaf107. eCollection 2025 Apr.
8
Role of Nanomedicine in Transforming Pharmacotherapy for Substance Use Disorder (SUD).纳米医学在改变物质使用障碍(SUD)药物治疗中的作用。
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2025 Mar-Apr;17(2):e70008. doi: 10.1002/wnan.70008.
9
Developing predictive models for µ opioid receptor binding using machine learning and deep learning techniques.使用机器学习和深度学习技术开发μ阿片受体结合的预测模型。
Exp Biol Med (Maywood). 2025 Mar 19;250:10359. doi: 10.3389/ebm.2025.10359. eCollection 2025.
10
Synergistic Epistasis and Systems Biology Approaches to Uncover a Pharmacogenomic Map Linked to Pain, Anti-Inflammatory and Immunomodulating Agents (PAIma) in a Healthy Cohort.协同上位性和系统生物学方法揭示健康队列中与疼痛、抗炎和免疫调节剂(PAIma)相关的药物基因组图谱。
Cell Mol Neurobiol. 2024 Nov 6;44(1):74. doi: 10.1007/s10571-024-01504-2.

本文引用的文献

1
How to Combat the Global Opioid Crisis.如何应对全球阿片类药物危机。
CPQ Neurol Psychol. 2023;5(4). Epub 2023 Jan 23.
2
Genetic Addiction Risk and Psychological Profiling Analyses for "Preaddiction" Severity Index.“预成瘾”严重程度指数的遗传成瘾风险与心理剖析分析
J Pers Med. 2022 Oct 27;12(11):1772. doi: 10.3390/jpm12111772.
3
High-frequency repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex reduces drug craving and improves decision-making ability in methamphetamine use disorder.左侧背外侧前额叶皮层高频重复经颅磁刺激可减少药物渴求,改善甲基苯丙胺使用障碍者的决策能力。
Psychiatry Res. 2022 Nov;317:114904. doi: 10.1016/j.psychres.2022.114904. Epub 2022 Oct 12.
4
Spironolactone as a potential new pharmacotherapy for alcohol use disorder: convergent evidence from rodent and human studies.螺内酯作为酒精使用障碍的一种潜在新的药物治疗方法:来自啮齿动物和人类研究的综合证据。
Mol Psychiatry. 2022 Nov;27(11):4642-4652. doi: 10.1038/s41380-022-01736-y. Epub 2022 Sep 20.
5
Why haven't we solved the addiction crisis?为什么我们还没有解决成瘾危机?
J Neurol Sci. 2022 Nov 15;442:120404. doi: 10.1016/j.jns.2022.120404. Epub 2022 Sep 2.
6
Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019".美国阿片类药物使用障碍的治疗差距是否缩小了?2010 年至 2019 年的年度评估。
Int J Drug Policy. 2022 Dec;110:103786. doi: 10.1016/j.drugpo.2022.103786. Epub 2022 Aug 4.
7
Preaddiction-A Missing Concept for Treating Substance Use Disorders.预测前——治疗物质使用障碍中一个缺失的概念。
JAMA Psychiatry. 2022 Aug 1;79(8):749-751. doi: 10.1001/jamapsychiatry.2022.1652.
8
Use of Medication for Opioid Use Disorder Among US Adolescents and Adults With Need for Opioid Treatment, 2019.2019 年美国需要阿片类药物治疗的青少年和成年人中,阿片类药物使用障碍药物治疗的使用情况。
JAMA Netw Open. 2022 Mar 1;5(3):e223821. doi: 10.1001/jamanetworkopen.2022.3821.
9
Repetitive Transcranial Magnetic Stimulation (rTMS) as a Promising Treatment for Craving in Stimulant Drugs and Behavioral Addiction: A Meta-Analysis.重复经颅磁刺激(rTMS)作为治疗兴奋剂药物成瘾和行为成瘾中渴望的一种有前景的疗法:一项荟萃分析。
J Clin Med. 2022 Jan 26;11(3):624. doi: 10.3390/jcm11030624.
10
Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review.氯胺酮用于治疗精神健康和物质使用障碍:全面系统评价
BJPsych Open. 2021 Dec 23;8(1):e19. doi: 10.1192/bjo.2021.1061.

阿片类药物使用障碍:当前趋势和潜在治疗方法。

Opioid use disorder: current trends and potential treatments.

机构信息

Department of Psychiatry, Brigham and Women's Hospital, Boston, MA, United States.

Department of Psychiatry, Washington University in St. Louis Euclid Ave, St. Louis, MO, United States.

出版信息

Front Public Health. 2024 Jan 25;11:1274719. doi: 10.3389/fpubh.2023.1274719. eCollection 2023.

DOI:10.3389/fpubh.2023.1274719
PMID:38332941
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10850316/
Abstract

Opioid use disorder (OUD) is a major public health threat, contributing to morbidity and mortality from addiction, overdose, and related medical conditions. Despite our increasing knowledge about the pathophysiology and existing medical treatments of OUD, it has remained a relapsing and remitting disorder for decades, with rising deaths from overdoses, rather than declining. The COVID-19 pandemic has accelerated the increase in overall substance use and interrupted access to treatment. If increased naloxone access, more buprenorphine prescribers, greater access to treatment, enhanced reimbursement, less stigma and various harm reduction strategies were effective for OUD, overdose deaths would not be at an all-time high. Different prevention and treatment approaches are needed to reverse the concerning trend in OUD. This article will review the recent trends and limitations on existing medications for OUD and briefly review novel approaches to treatment that have the potential to be more durable and effective than existing medications. The focus will be on promising interventional treatments, psychedelics, neuroimmune, neutraceutical, and electromagnetic therapies. At different phases of investigation and FDA approval, these novel approaches have the potential to not just reduce overdoses and deaths, but attenuate OUD, as well as address existing comorbid disorders.

摘要

阿片类使用障碍(OUD)是一个主要的公共卫生威胁,导致成瘾、过量用药和相关医疗状况的发病率和死亡率上升。尽管我们对 OUD 的病理生理学和现有医疗治疗方法的了解不断增加,但几十年来,它仍然是一种反复发作和缓解的疾病,过量用药导致的死亡人数呈上升趋势,而不是下降。COVID-19 大流行加速了整体物质使用的增加,并中断了治疗的获取。如果增加纳洛酮的获取、更多的丁丙诺啡开处方者、更多的治疗机会、增强报销、减少污名化以及各种减少伤害的策略对 OUD 有效,那么过量用药死亡人数就不会达到历史最高水平。需要采取不同的预防和治疗方法来扭转 OUD 令人担忧的趋势。本文将回顾 OUD 现有药物的最新趋势和局限性,并简要回顾有潜力比现有药物更持久和有效的新型治疗方法。重点将放在有前途的干预性治疗、迷幻药、神经免疫、营养神经和电磁疗法上。在不同的研究阶段和 FDA 批准阶段,这些新方法有可能不仅减少过量用药和死亡,还能减轻 OUD,并解决现有的合并症。